Press Releases April 7, 2026 07:47 AM

Virtuix to Present at Exclusive Investor Forum at Mar-a-Lago Club in Palm Beach, Florida

Virtuix CEO to Present at Exclusive Investor and Government Forum Highlighting Strategic Defense Partnerships and Growth Initiatives

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
VTIX

Virtuix Inc. announced that CEO Jan Goetgeluk will present at a private investor forum at Mar-a-Lago and an investor lunch in West Palm Beach on April 16, 2026. The presentations will focus on Virtuix's expanding traction in the defense sector through sales and partnerships with the U.S. Army, Navy, and Marine Corps, its participation in Meta's 'Made for Meta' program, and additional strategic initiatives driving growth. The invitation to these exclusive events underscores growing market recognition of Virtuix's leadership in immersive VR technologies for gaming, fitness, enterprise, and defense.

Virtuix to Present at Exclusive Investor Forum at Mar-a-Lago Club in Palm Beach, Florida
VTIX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Virtuix's Omni omni-directional treadmills are gaining significant adoption in the U.S. defense sector, with contracts and partnerships involving the Army, Navy, and Marine Corps.
  • The company is participating in Meta’s "Made for Meta" program, highlighting its integration with leading XR platforms and commitment to innovation in extended reality and AI.
  • The invitation to present at high-profile, private investor and government forums like Mar-a-Lago indicates strong investor and governmental interest in Virtuix's products and growth potential.

Chief Executive Officer Jan Goetgeluk to Present at Private, Invitation-Only Dinner at Mar-a-Lago with Investors and Senior Government Officials

AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, today announced that Chief Executive Officer Jan Goetgeluk will present at a private, invitation-only roundtable taking place April 16, 2026, at the Mar-a-Lago Club in Palm Beach, Florida.

Mr. Goetgeluk will meet with an exclusive group of institutional investors, high-net-worth individuals and senior government officials at Mar-a-Lago and also present at an investor lunch in West Palm Beach earlier in the day on April 16, 2026. Mr. Goetgeluk will discuss the Company's growing traction for the Omni technology in the defense sector, with recent sales and partnerships with the U.S. Army, Navy, and Marine Corps, as well as Virtuix’s participation in Meta's "Made for Meta" program and additional strategic initiatives and upcoming milestones.

Virtuix’s invitation to present at Mar-a-Lago and West Palm Beach reflects growing market recognition for the company’s leadership position at the intersection of immersive gaming, fitness, and simulation for enterprise and defense. Both investor events are hosted by Money Channel NYC.

About Virtuix

Virtuix Inc. (NASDAQ: VTIX) is a leading manufacturer of full-body virtual reality systems for consumer, enterprise, and defense markets. The company's premier portfolio of "Omni" omni-directional treadmills enables players to walk and run in 360 degrees inside video games and other virtual reality applications. With a commitment to innovation, Virtuix continues to push the boundaries of XR and AI, delivering immersive experiences to users worldwide. For more information, visit virtuix.com.

Visit Us on Social Media:

LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
[email protected]

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]


Risks

  • Virtuix's continued success depends on maintaining and expanding its defense sector partnerships, which could be impacted by government budget changes or policy shifts.
  • The company's market position in the highly competitive VR and XR industries requires ongoing innovation; failure to keep pace technologically could hinder growth.
  • As a publicly traded company relying on new strategic initiatives and milestones, delays or failures in execution could negatively affect investor confidence and market valuation.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026